Dedicated to **human health!**

**UNiMED PHARM INC.** is a future-oriented and honest pharmaceutical company founded in 1990 under the faith of “health in your life.”

UNiMED PHARM INC. offers diversity of drugs ranging from antibiotics, chemotherapeutics, gastrointestinal system agents, neuro-muscular system agents, cardiovascular system agents, respiratory system, to ophthalmic preparations. UNiMED puts effort into improving healthy life with the products such as human placenta healthy drink which we ensure the safety and quality. In addition, We produce high quality Hyaluronate Acid products such as joint-function improvement agents, ophthalmic surgery preparations and surgical adjuvants.

### Sales Growth

<table>
<thead>
<tr>
<th>Year</th>
<th>Total sales turnover (Million US$)</th>
<th>Growth Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>49.00</td>
<td>22.5%</td>
</tr>
<tr>
<td>2008</td>
<td>56.09</td>
<td>14.28%</td>
</tr>
<tr>
<td>2009</td>
<td>75.70</td>
<td>35.17%</td>
</tr>
<tr>
<td>2010</td>
<td>85.30</td>
<td>12.68%</td>
</tr>
<tr>
<td>2011</td>
<td>100.00</td>
<td>17.23%</td>
</tr>
<tr>
<td>2012</td>
<td>108.86</td>
<td>8.86%</td>
</tr>
<tr>
<td>2013</td>
<td>110.00</td>
<td>1.05%</td>
</tr>
<tr>
<td>2014</td>
<td>115.10</td>
<td>4.64%</td>
</tr>
</tbody>
</table>
UNIMED gives priority to R&D and the quality of products. We devote to formulate innovative medicines and high quality products. As part of our endeavor, we have constructed a new factory equipped with state-of-the-art facilities in Osong Bio-Health Science Technopolis, Korea.
 Blow Fill Seal system (BFS)

Unit dose ophthalmic solution (BFS) 1,200,000,000 ampoules/Year

Preservative – free preparations with BFS Facility

Unit dose Ophthalmic Solution can be used while wearing contact lenses.

### Unial Dispo Ophthalmic Solution 0.5mL each
- Sodium hyaluronate 1mg/mL
  - Temporary relief of burning, irritation and discomfort due to dry eye.

### Onetime Fresh Ophthalmic Solution 0.5mL each
- Carboxymethylcellulose 5mg/mL
  - Sodium hyaluronate 1.8mg/mL 3mg/mL
  - For the adjuvant treatment of corneal and conjunctival epithelial injuries and dry eyes.

### Patadin Ophthalmic Solution 0.5mL each
- Olopatadine HCl 1.11mg/mL
  - Symptomatic treatment of seasonal allergic conjunctivitis.

### Product | Contents(per mL) | Indications
--- | --- | ---
Unimed Fluorometholone | Fluorometholone 1mg | Inflammation of posterior and anterior segment of the globe (palpebral inflammation, conjunctivitis, cornitis, scleritis, episcleritis, iritis, uveitis, post-operative inflammation etc.)
Unimelone | Fluorometholone 1mg, Tetrahydrozoline 0.25mg | Acute noninfectious conjunctivitis and allergic keratitis with serious edema and hyperemia.
Uniten | Ketotifen Fumarate 0.69mg | Symptomatic treatment of allergic conjunctivitis.
Octacin | Ofloxacin 3mg | Blepharitis, hordeolum, dacryocystitis, conjunctivitis, tarsadenitis, keratitis, keratohealcosis
Tobacin | Tobramycin 3mg | Blepharitis, hordeolum, dacryocystitis, conjunctivitis, tarsadenitis, keratitis, keratohealcosis
Lectacin | Levofoxxacin 3mg | Blepharitis, hordeolum, dacryocystitis, conjunctivitis, tarsadenitis, keratitis, keratohealcosis, aseptic treatment in ophthalmic operation
Pre-Filled Syringe (PFS)

Pre-Filled preparations

Orthopedic Preparations
Treatment of pain in osteoarthritis (OA) of the knee, and periarthritis of the shoulders

- **Unilon dispo injection**
  - 5-week therapy for joint movement
  - Sodium hyaluronate 25mg/2.5ml
  - MW : 1MDa

- **Hylan dispo injection**
  - 3-week therapy for joint movement
  - Sodium hyaluronate 20mg/2ml
  - MW : 3MDa

Ophthalmic Preparation
Surgical adjuvant for cataract extraction, IOL implantation and other various ophthalmic surgeries

- **Unial injection**
  - Excellent buffer for ophthalmology operations
  - Sodium hyaluronate 16.5mg/1.1ml

- **Unibon injection**
  - Anti-osteoporosis for women after menopausal syndrome
  - Ibandronate sodium monohydrate 3.375mg (ibandronic acid 3mg)

- **PROTADE injection**
  - Anti-Adhesion superior to other complex ingredients
  - Sodium hyaluronate 1.1ml, 1.4ml, 3.0ml/1s

- **ENDO EASE**
  - Excellent swelling for endoscopic resection
  - Sodium hyaluronate 10V(2ml/1V), 5V(10ml, 20ml/1V)
Human placenta preparation

Placenta Products

**Unicenta Oral Solution**

- **Active Ingredient**
  - Placenta ext. 7.5mg, Thiamine Nitrate, Riboflavin Sodium Phosphate, Pyridoxine HCl, and Nicotinamide
- **Packing**
  - 20ml / Bottle X 30’s, 20ml / Bottle X 60’s

**Placenta Ext. Inj.**

- **Active Ingredient**
  - Human Placenta Ext. 2ml / Ampoule
- **Packing**
  - 2ml / Ampoule X 50’s

**Unicenta oral solution (Human placenta oral solution)**

- Efficacy and Safety Test of Unicenta solution on fatigue: A Double-Blind, Randomized, Placebo-controlled study

![Graph showing CIS Score improvement(%) for Unicenta, Placenta ext., and Placebo]


**Unicenta injection (Human placenta injection)**

- Proof of Excellent efficacy greater or equivalent to Melsmon injection by a comparison test for the improvement of the menopausal symptoms and hot flushes during day and night

![Graph showing Kupperman index Excellent decrease effectiveness for Unicenta Injection and Melsmon Injection]

Kupperman index Excellent decrease effectiveness

- **KI Score**
  - Baseline: 30.64±7.99, Visit 5: 20.43±9.88, Visit 8: 13.38±5.77
  - **KI decline in total**
    - Unicenta Injection: 17.26±6.4, Melsmon Injection: 16.92±3.33
### R&D Pipe Line

<table>
<thead>
<tr>
<th>Product</th>
<th>Therapy Area</th>
<th>Ingredients</th>
<th>Phase</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dinuro</td>
<td>Diabetic neuropathy</td>
<td>Pregabalin + Thiotic Acid</td>
<td>Phase I</td>
<td>Completed</td>
</tr>
<tr>
<td></td>
<td>Therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unicenta</td>
<td>Women's Health</td>
<td>Placenta Injection</td>
<td>Phase III</td>
<td>Completed</td>
</tr>
<tr>
<td>Unicenta Solution</td>
<td>Women's Health</td>
<td>Placenta Oral Solution</td>
<td>Phase IV</td>
<td>Ongoing</td>
</tr>
<tr>
<td>UNI-C Injection</td>
<td>Nutritional Disorders</td>
<td>Ascorbic Acid</td>
<td>PMS</td>
<td>Completed</td>
</tr>
<tr>
<td></td>
<td>Immunology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UNIBUERGER</td>
<td>Cardiovascular</td>
<td>Beraprost Sodium</td>
<td>Phase IV</td>
<td>Planned</td>
</tr>
<tr>
<td>LECTACIN Tab.</td>
<td>Infectious Disease</td>
<td>Levofloxacin</td>
<td>Phase IV</td>
<td>Completed</td>
</tr>
<tr>
<td>LECTACIN Inj.</td>
<td>Infectious Disease</td>
<td>Levofloxacin</td>
<td>Phase IV</td>
<td>Completed</td>
</tr>
<tr>
<td>Endo-Ease</td>
<td>EMR/ESD : Medical device</td>
<td>Hyaluronic Acid</td>
<td>Phase IV</td>
<td>Planned</td>
</tr>
<tr>
<td>Protad Inj.</td>
<td>Anti-adhesion Adjuvant: Medical device</td>
<td>Hyaluronic Acid</td>
<td>Phase III</td>
<td>Completed</td>
</tr>
<tr>
<td>HBT-ENT-001</td>
<td>Cardiovascular</td>
<td>vitis vinifera ext.</td>
<td>Phase III</td>
<td>Ongoing</td>
</tr>
</tbody>
</table>